快速检索
年期检索
摘要： Objective To explore the benefits and risks of PD-1/PD-L1 inhibitors Atezolizumab and Nivolumab in the treatment of non-squamous non-small cell lung cancer and provide some references for clinicians. Methods Based on the data results of relevant studies published by ClinicalTrical.gov in the US clinical trial database and foreign peer-reviewed journals, the internationally recognized multi-criteria decision analysis (MCDA) model was used to assess the benefit and risk of PD-1/PD-L1 inhibitors for non-squamous non-small lung cancer comprehensively. Finally, a sensitivity analysis was performed to test the sensitivity of the weight to the evaluation. Results and Conclusion The benefit-risk evaluation result of Atezolizumab for the treatment of non-squamous non-small cell lung cancer is better than that of Nivolumab. Specifically, Atezolizumab has more benefits than Nivolumab with a lower risk. The results of MCDA model in drug benefit and risk evaluation are easy to understand. However, the selection of indicators in the model and the degree of data acquisition are limited. The evaluation results of the MCDA model should be comprehensively viewed with other evaluations to make decisions objectively.
